The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients

被引：0
|
作者：
Khalid Almutairi
Johannes Nossent
David B. Preen
Helen Keen
Charles Inderjeeth
机构：
[1] The University of Western Australia,School of Medicine
[2] King Fahd Specialist Hospital,School of Population and Global Health
[3] Sir Charles Gairdner and Osborne Park Health Care Group,undefined
[4] The University of Western Australia,undefined
[5] Fiona Stanley Hospital,undefined
来源：
Rheumatology International | 2022年 / 42卷
关键词：
Rheumatoid arthritis; Hospital admissions; Anti-rheumatic drugs utilization; Direct costs;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The Australian Pharmaceutical Benefits Scheme (PBS) has subsidised biological therapy since 2003. We investigated the association between biological therapy for RA hospitalisation rates and health-care costs.
引用
收藏
页码：2027 / 2037
页数：10
相关论文
共 50 条
  • [1] The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients
    Almutairi, Khalid
    Nossent, Johannes
    Preen, David B.
    Keen, Helen
    Inderjeeth, Charles
    RHEUMATOLOGY INTERNATIONAL, 2022, 42 (11) : 2027 - 2037
  • [2] Direct costs of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care center
    ArizaAriza, R
    MestanzaPeralta, M
    Cardiel, MH
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1997, 15 (01) : 75 - 78
  • [3] Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey
    Baser O.
    Baser E.
    Altinbas A.
    Burkan A.
    Health Economics Review, 3 (1) : 1 - 7
  • [4] Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis
    Potera, Joanna
    Kambhatla, Soumyasri
    Gauto-Mariotti, Estefania
    Manadan, Augustine
    CLINICAL RHEUMATOLOGY, 2021, 40 (12) : 4845 - 4851
  • [5] Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis
    Joanna Potera
    Soumyasri Kambhatla
    Estefania Gauto-Mariotti
    Augustine Manadan
    Clinical Rheumatology, 2021, 40 : 4845 - 4851
  • [6] Drug usage analysis and health care resources consumption in naive patients with rheumatoid arthritis
    Sangiorgi, Diego
    Benucci, Maurizio
    Nappi, Carmela
    Perrone, Valentina
    Buda, Stefano
    Degli Esposti, Luca
    BIOLOGICS-TARGETS & THERAPY, 2015, 9 : 119 - 127
  • [7] Indirect costs assessment and intangible costs description of rheumatoid arthritis patients with biological therapy in Morocco: ECORAM Study
    Zarrik, Hanae
    Hassani, Abha Cherkani
    Rkain, Hanane
    Allali, Fadoua
    Bahiri, Rachid
    Ahid, Samir
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (10)
  • [8] BIOLOGICAL THERAPY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Del Pozo Ruiz, Javier Jose
    Ortega Valin, Luis
    Perez Sandoval, Trinidad
    Martin Sanchez, Vicente
    de Urbina Gonzalez, Ortiz Juan
    Gutierrez Gutierrez, Esperanza
    ATENCION FARMACEUTICA, 2009, 11 (06): : 368 - +
  • [9] Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto
    Borras-Blasco, Joaquin
    Dolores-Elvira Castera, M.
    Cortes, Xavier
    Dolores Rosique-Robles, J.
    Javier Abad, F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (11) : 1561 - 1567
  • [10] Association between rheumatoid factors and proinflammatory biomarkers with implant health in rheumatoid arthritis patients with dental implants
    Alenazi, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (22) : 7014 - 7021
12345